Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth A Mullen

Showing results (21-30 of 78) with videos related to

Pageof 8
Sort By:
Journal of Pediatric Urology|May 28, 2014
Feasibility of using CT volume as a predictor of specimen weight in a subgroup of patients with low risk Wilms tumors registered on COG Study AREN03B2: implications for central venous catheter placementFernando A Ferrer, Katherine W Herbst, Conrad V Fernandez, et al.
Journal of the National Cancer Institute|March 28, 2024
Response of bilateral Wilms tumor to chemotherapy suggests histologic subtype and guides treatmentColton Duncan, Suraj Sarvode Mothi, Teresa C Santiago, et al.
Pediatric Blood & Cancer|July 27, 2025
Anti-Tumor Activity of Paclitaxel-Containing Regimens in Recurrent/Refractory Wilms TumorAlissa Groisser, Amy Frantz, James I Geller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2022
Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533Laura M Madanat-Harjuoja, Lindsay A Renfro, Kelly Klega, et al.
Cancer|April 9, 2020
Outcome analysis of stage I epithelial-predominant favorable-histology Wilms tumors: A report from Children's Oncology Group study AREN03B2Lauren N Parsons, Elizabeth A Mullen, James I Geller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2018
Impact of Surveillance Imaging Modality on Survival After Recurrence in Patients With Favorable-Histology Wilms Tumor: A Report From the Children's Oncology GroupElizabeth A Mullen, Yueh-Yun Chi, Emily Hibbitts, et al.
Pediatric Radiology|July 10, 2017
Imaging of renal medullary carcinoma in children and young adults: a report from the Children's Oncology GroupJesse K Sandberg, Elizabeth A Mullen, Mariana M Cajaiba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Topotecan is active against Wilms' tumor: results of a multi-institutional phase II studyMonika L Metzger, Clinton F Stewart, Burgess B Freeman, et al.
Cell Reports. Medicine|May 26, 2022
Genetic changes associated with relapse in favorable histology Wilms tumor: A Children's Oncology Group AREN03B2 studySamantha Gadd, Vicki Huff, Andrew D Skol, et al.
Cancer|June 16, 2018
The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testingMariana M Cajaiba, Lisa M Dyer, James I Geller, et al.
Pageof 8

Showing results (21-30 of 78) with videos related to

Sort By:
Pageof 8
Journal of Pediatric Urology|May 28, 2014
Feasibility of using CT volume as a predictor of specimen weight in a subgroup of patients with low risk Wilms tumors registered on COG Study AREN03B2: implications for central venous catheter placementFernando A Ferrer, Katherine W Herbst, Conrad V Fernandez, et al.
Journal of the National Cancer Institute|March 28, 2024
Response of bilateral Wilms tumor to chemotherapy suggests histologic subtype and guides treatmentColton Duncan, Suraj Sarvode Mothi, Teresa C Santiago, et al.
Pediatric Blood & Cancer|July 27, 2025
Anti-Tumor Activity of Paclitaxel-Containing Regimens in Recurrent/Refractory Wilms TumorAlissa Groisser, Amy Frantz, James I Geller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2022
Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533Laura M Madanat-Harjuoja, Lindsay A Renfro, Kelly Klega, et al.
Cancer|April 9, 2020
Outcome analysis of stage I epithelial-predominant favorable-histology Wilms tumors: A report from Children's Oncology Group study AREN03B2Lauren N Parsons, Elizabeth A Mullen, James I Geller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2018
Impact of Surveillance Imaging Modality on Survival After Recurrence in Patients With Favorable-Histology Wilms Tumor: A Report From the Children's Oncology GroupElizabeth A Mullen, Yueh-Yun Chi, Emily Hibbitts, et al.
Pediatric Radiology|July 10, 2017
Imaging of renal medullary carcinoma in children and young adults: a report from the Children's Oncology GroupJesse K Sandberg, Elizabeth A Mullen, Mariana M Cajaiba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Topotecan is active against Wilms' tumor: results of a multi-institutional phase II studyMonika L Metzger, Clinton F Stewart, Burgess B Freeman, et al.
Cell Reports. Medicine|May 26, 2022
Genetic changes associated with relapse in favorable histology Wilms tumor: A Children's Oncology Group AREN03B2 studySamantha Gadd, Vicki Huff, Andrew D Skol, et al.
Cancer|June 16, 2018
The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testingMariana M Cajaiba, Lisa M Dyer, James I Geller, et al.
Pageof 8